Ozempic and GLP-1 Drug Costs in 2026: Complete Savings Guide
Updated September 2026 · 11 min read
GLP-1 medications like Ozempic, Wegovy, Mounjaro, and Zepbound have transformed diabetes and weight management treatment, but their costs are reshaping the entire healthcare system. National GLP-1 spending surged over 500% between 2018 and 2023, from $13.7 billion to $71.7 billion. These drugs now account for an estimated 14% of all prescription drug spending in America — and that cost is driving up insurance premiums for everyone. Here is everything you need to know about GLP-1 costs in 2026 and how to get the best price.
Find the cheapest way to fill your prescription — insurance vs GoodRx vs Cost Plus vs manufacturer programs.
What GLP-1 Drugs Cost in 2026
Without Insurance (Retail Prices)
- Ozempic (semaglutide injection): $800 to $1,350 per month at retail pharmacies. Novo Nordisk self-pay price through NovoCare: $349 per month.
- Wegovy (semaglutide injection for weight loss): similar pricing to Ozempic. Self-pay through NovoCare: $349 per month.
- Wegovy pill (oral semaglutide, launched 2026): self-pay starts at $149 per month for the 1.5mg dose, increasing with higher doses.
- Mounjaro (tirzepatide): $800 to $1,200 per month retail.
- Zepbound (tirzepatide for weight loss): similar pricing to Mounjaro.
With Insurance
If your insurance covers GLP-1 medications, your cost could range from $25 to $250 per month depending on your plan formulary, tier placement, and deductible. However, 88% of insurance plans place additional restrictions on coverage for weight loss indications — meaning you may need prior authorization, step therapy (trying cheaper drugs first), or a specific diagnosis to get coverage.
Compare your insurance copay against discount options with our Prescription Cost Comparison tool.
With Discount Cards
- GoodRx: Ozempic from around $199 per month, Wegovy pill from $149 per month. GoodRx saves people more than $650 per month on average across the top 7 GLP-1 medications compared to retail.
- Cost Plus Drugs: check availability — prices are at cost plus 15% markup plus a flat pharmacy fee.
Medicare GLP-1 Bridge Program (New in 2026)
Starting July 2026, Medicare launched the GLP-1 Bridge program offering a flat $50 per month copay for certain GLP-1 weight loss medications. Key details:
- Eligible drugs: Wegovy and Zepbound (for weight management). Ozempic is NOT included because it is indicated for diabetes and already covered under standard Part D.
- Eligibility: BMI of 35 or higher, no GLP-1 prescription filled under Part D earlier in 2026, and no existing diagnosis (like Type 2 diabetes) that already qualifies for GLP-1 coverage under standard Part D.
- Important: the $50 copay does NOT count toward your Part D deductible or annual out-of-pocket spending cap. It is outside your regular benefits.
- Duration: temporary program running through 2027.
Do you meet the BMI requirement? Check with our free BMI Calculator.
Manufacturer Patient Assistance Programs
Both major GLP-1 manufacturers offer patient assistance programs with surprisingly generous income thresholds:
- Novo Nordisk (Ozempic/Wegovy): patients with household income up to 400% of the Federal Poverty Level (roughly $62,000 for a single person in 2026) may qualify for costs as low as $0 to $25 per month.
- Eli Lilly (Mounjaro/Zepbound): similar income-based assistance programs available.
Contact the manufacturers directly or ask your doctor about patient assistance applications.
How GLP-1 Costs Affect YOUR Insurance Premiums
Even if you never take a GLP-1 medication, you are paying for them. The massive increase in GLP-1 spending is one of the primary drivers of the 2026-2027 premium increases across all types of insurance. KFF and industry analysts have explicitly cited GLP-1 costs as a factor in the 15-20% ACA premium increases and 8-10% employer plan increases.
This makes it more important than ever to optimize your own healthcare costs. Use these tools to make sure you are not overpaying:
- Out-of-Pocket Calculator — see your actual cost exposure
- HSA Calculator — offset rising costs with tax-free savings
- ACA Subsidy Calculator — check if rising premiums qualify you for help
- Prescription Cost Comparison — find the cheapest option for any medication
Medicare Negotiated Drug Prices (2026)
In a separate but related development, Medicare-negotiated drug prices for 10 high-cost medications took effect January 1, 2026. These include Stelara, Enbrel, Januvia, and Eliquis. CMS estimates these negotiations will save Medicare beneficiaries $1.5 billion in out-of-pocket costs, with prices for the negotiated drugs falling more than 50% on average.
Additionally, Medicare negotiated prices for Ozempic, Rybelsus, and Wegovy in the second round of negotiations, with new prices of $274 for a 30-day supply taking effect in 2027.
The Bottom Line: How to Get the Best Price
- Check your insurance coverage first — including prior authorization requirements and formulary tier
- Compare your copay against discount options using our Prescription Cost Comparison tool
- Apply for manufacturer patient assistance if your income is under 400% FPL
- Check the Medicare GLP-1 Bridge if you are on Medicare and have BMI 35+
- Consider the Wegovy pill at $149/month self-pay — significantly cheaper than injections
- Remember the deductible trade-off: discount card purchases do not count toward your deductible. If you expect to meet your deductible anyway, using insurance may be strategically better even at a higher per-fill cost
Sources: GoodRx, HFMA, CMS, KFF, AARP, Medical News Today, Aon Research, Drugs.com. Drug prices are approximate and vary by pharmacy, dose, and location. This article is for educational purposes only and is not medical or financial advice. Always consult your healthcare provider before starting or changing medications.